The Latin America, Middle East and Africa Continuous Glucose Monitoring Device Market is expected to witness market growth of 13.4% CAGR during the forecast period (2020-2026).
The CGM displays a glucose trend graph and direction arrows that enable people with diabetes to predict rising glucose levels and lows, thus alerting the user at distracted periods such as playing, sleeping or exercising. The demand for CGM products is projected to gain significant momentum due to collaborations between endocrinologists, credentialed diabetes educators, and diabetes prevention stakeholder organizations.
Growing cases of diabetes have accelerated the market, along with the rising use of continuous glucose monitoring (CGM) devices. CGM devices are minimally invasive and provide a simple and reliable approach to diabetes treatment. They can also track dramatic changes in levels of blood glucose, thereby avoiding hypoglycemic disorders.
Through the assistance of a sensor, these instruments enable the analysis of blood glucose levels at different time intervals. Respective readings fed in via a wireless network to a diabetes treatment software allow patients to better understand the condition, thereby allowing them to treat it more effectively.The main risk factors associated with diabetes problems are smoking, obesity, physical inactivity, and high blood pressure and elevated cholesterol.
Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson
Scope of the Study
Market Segmentation:
By Component
By End User
By Country
Companies Profiled:
Unique Offerings from the Publisher:
The CGM displays a glucose trend graph and direction arrows that enable people with diabetes to predict rising glucose levels and lows, thus alerting the user at distracted periods such as playing, sleeping or exercising. The demand for CGM products is projected to gain significant momentum due to collaborations between endocrinologists, credentialed diabetes educators, and diabetes prevention stakeholder organizations.
Growing cases of diabetes have accelerated the market, along with the rising use of continuous glucose monitoring (CGM) devices. CGM devices are minimally invasive and provide a simple and reliable approach to diabetes treatment. They can also track dramatic changes in levels of blood glucose, thereby avoiding hypoglycemic disorders.
Through the assistance of a sensor, these instruments enable the analysis of blood glucose levels at different time intervals. Respective readings fed in via a wireless network to a diabetes treatment software allow patients to better understand the condition, thereby allowing them to treat it more effectively.The main risk factors associated with diabetes problems are smoking, obesity, physical inactivity, and high blood pressure and elevated cholesterol.
Based on Component, the market is segmented into Sensors, Transmitters, and Receivers. Based on End User, the market is segmented into Hospitals, Homecare Settings and Other End Users. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Abbott Laboratories, Medtronic PLC, F. Hoffmann-La Roche Ltd., Novo Nordisk A/S, DexCom, Inc., Ypsomed AG, Senseonics Holdings, Inc., GlySens, Incorporated, A. Menarini Diagnostics Ltd. (The Menarini Group), Echo Therapeutics, Inc., Johnson and Johnson
Scope of the Study
Market Segmentation:
By Component
- Sensors
- Transmitters and
- Receivers
By End User
- Hospitals
- Homecare Settings and
- Other End Users
By Country
- Brazil
- Argentina
- UAE
- Saudi Arabia
- South Africa
- Nigeria
- Rest of LAMEA
Companies Profiled:
- Abbott Laboratories
- Medtronic PLC
- F. Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- DexCom, Inc.
- Ypsomed AG
- Senseonics Holdings, Inc.
- GlySens, Incorporated
- A. Menarini Diagnostics Ltd. (The Menarini Group)
- Echo Therapeutics, Inc.
- Johnson and Johnson
Unique Offerings from the Publisher:
- Exhaustive coverage
- Highest number of market tables and figures
- Subscription based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Table of Contents
Chapter 1. Market Scope & Methodology
Chapter 2. Market Overview
Chapter 3. LAMEA Continuous Glucose Monitoring Device Market by Component
Chapter 4. LAMEA Continuous Glucose Monitoring Device Market by End-user
Chapter 5. LAMEA Continuous Glucose Monitoring Device Market by Country
Chapter 6. Company Profiles
Companies Mentioned
- Abbott Laboratories
- Medtronic PLC
- F. Hoffmann-La Roche Ltd.
- Novo Nordisk A/S
- DexCom, Inc.
- Ypsomed AG
- Senseonics Holdings, Inc.
- GlySens, Incorporated
- A. Menarini Diagnostics Ltd. (The Menarini Group)
- Echo Therapeutics, Inc.
- Johnson and Johnson
Methodology
LOADING...
